ArticleMedicine2025
Single-cell atlas of COVID-19 based on multiple sample integration.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
This study addressed the significant challenges in understanding the specific immune landscape and predicting patient outcomes of COVID-19, particularly in severe cases. To support clinical practice, we aimed to build a comprehensive single-cell atlas of the disease and develop a predictive model for severe patient outcomes. We collected single-cell RNA sequencing data from COVID-19 patients, influenza patients, and healthy controls. Our analysis encompassed alterations in cell abundance, transcriptomic profiles, and pathway activities across these groups. We then constructed a logistic regression model to predict the prognosis of severe COVID-19 patients, evaluating its performance using sensitivity, specificity, and area under the curve (AUC) metrics. Our integrated dataset comprised 434,703 cells from 233 samples across 8 datasets, categorized into major cell types including T/natural killer cells, B cells, myeloid cells, epithelial cells, and platelets. T/NK cells and myeloid cells constituted the largest proportions and exhibited the most significant changes in abundance among the different groups. We identified substantial alterations in inflammatory genes and metabolic pathways across various T cell and myeloid cell subtypes, with differential expression of these genes also correlating with COVID-19 severity and patient outcomes. The developed logistic regression model, incorporating the genes IL1R2, PI3, IGHG3, and CTTN, demonstrated a sensitivity of 80.0% and an AUC of 70.5% in the training set. These results were consistent in the test set, with a sensitivity of 81.1% and an AUC of 70.6%. By depicting a comprehensive single-cell atlas of COVID-19, this work unravels the complex cellular dynamics underlying the disease, thereby advancing our understanding of its mechanisms. The developed model shows promise for predicting outcomes in severe COVID-19 patients, which could facilitate clinical decision-making and ultimately benefit patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.